Boronic acid-tethered amphiphilic hyaluronic acid derivative-based nanoassemblies for tumor targeting and penetration

Jeong, Jae Young; Hong, Eock Kee; Lee, Song Yi; Lee, Jae-Young; Song, Jae-Hyoung; Ko, Seung-Hak; Shim, Jae-Seong; Choe, Senyon; Kim, Dae‐Duk; Ko, Hyun–Jeong; Hyun‐Jong, Cho

doi:10.1016/j.actbio.2017.02.030

Cited by 57 publications

(53 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The final nanoassemblies formed through amide linkage between APBA and HA exhibited enhanced accumulation of HA-APBA-MB nanoassemblies inside the tumour cells compared to the free MB which was attributed to the CD44-RME, in addition to sialic acid-pheylboronic acid interaction. These results clearly revealed proficient ability of HA as a tumour-targeting agent [30]. P-glycoproteins (p-gp) tend to play crucial roles in developing multidrug resistance (MDR) against chemotherapeutic agents by effluxing out anticancer drugs from the cancer cells.…”

Section: Treatment Of Breast Cancer: Ha-conjugated Multifunctional Namentioning

confidence: 93%

“…Additionally, significantly over-expressed CD44 receptors form the hallmark of various breast cancer subtypes, including TNBC. To achieve tumour-specific targetability, reduced drug resistance and improve anticancer efficacy, several HA-conjugated or -decorated nanocarrier systems, such as nanoassemblies [30], SLNs [31], NPs [32], graphene oxide (GO) NPs [33], poly-lactide-co-glycolide (PLGA)-NPs [34], micelles [35,36] and NLCs [37] have been fabricated for treatment of breast cancer.…”

Section: Treatment Of Breast Cancer: Ha-conjugated Multifunctional Namentioning

confidence: 99%

“…Recently, Jeong et al [30] prepared novel aminomethylboronic acid (APBA) conjugated HA ceramide (HACE) based nanoassemblies for targeted delivery of the natural anticancer compound, Manassantin B, against CD44 over-expressed MDA-MB 231 breast cancer cells. Manassantin B is a lignin extracted from the roots of Saurusus chinensis.…”

Section: Treatment Of Breast Cancer: Ha-conjugated Multifunctional Namentioning

confidence: 99%

See 2 more Smart Citations

New developments and clinical transition of hyaluronic acid-based nanotherapeutics for treatment of cancer: reversing multidrug resistance, tumour-specific targetability and improved anticancer efficacy

Safdar

Hussain

Abourehab

et al. 2017

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

This review aims to overview and critically analyses recent developments in achieving tumour-specific delivery of anticancer agents, maximizing anticancer efficacy, and mitigating tumour progression and off-target effects. Stemming from critical needs to develop target-specific delivery vehicles in cancer therapy, various hyaluronic acid (HA)-conjugated nanomedicines have been fabricated owing to their biocompatibility, safety, tumour-specific targetability of drugs and genes, and proficient interaction with cluster-determinant-44 (CD44) receptors over-expressed on the surface of tumour cells. HA-based conjugation or surface modulation of anticancer drugs encapsulated nanocarriers have shown promising efficacy against the various types of carcinomas of liver, breast, colorectal, pancreatic, lung, skin, ovarian, cervical, head and neck and gastric. The success of this emerging platform is assessed in achieving the rapid internalization of anticancer payloads into the tumour cells, impeding cancer cells division and proliferation, induction of cancer-specific apoptosis and prevention of metastasis (tumour progression). This review extends detailed insight into the engineering of HA-based nanomedicines, characterization, utilization for the diagnosis or treatment of CD44 over-expressing cancer subtypes and emphasizing the transition of nanomedicines to clinical cancer therapy.

show abstract

Section: Treatment Of Breast Cancer: Ha-conjugated Multifunctional Namentioning

confidence: 93%

Section: Treatment Of Breast Cancer: Ha-conjugated Multifunctional Namentioning

confidence: 99%

Section: Treatment Of Breast Cancer: Ha-conjugated Multifunctional Namentioning

confidence: 99%

See 1 more Smart Citation

New developments and clinical transition of hyaluronic acid-based nanotherapeutics for treatment of cancer: reversing multidrug resistance, tumour-specific targetability and improved anticancer efficacy

Safdar

Hussain

Abourehab

et al. 2017

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

show abstract

“…(3-Aminomethylphenyl)boronic acid (AMPB)-installed hyaluronic acid (HA)-ceramide (HACE)-based NPs, including manassantin B (MB), forming HACE-AMPB/MB NPs (239 nm), when targeted on cancer cells revealed increased cellular accumulation and efficient antitumor activity and were hypothesized to react with sialic acid overexpressed in CD44 receptor-positive human adenocarcinoma cells [80].…”

Section: Nanotechnology Bioimaging Application Detection Of Cellularmentioning

confidence: 99%

Nanotechnology and sialic acid biology

Ghosh¹

2020

Sialic Acids and Sialoglycoconjugates in the Biology of Life, Health and Disease

View full text Add to dashboard Cite

“…Drug delivery efficacy significantly depends on the uptake of drugs in cells [28]. Effective uptake of drugs is a very crucial issue for favorable treatment outcoming.…”

Section: Selective Uptake Of Ha-se@ptx Nanoparticlesmentioning

confidence: 99%

Hyaluronic acid-modified selenium nanoparticles for enhancing the therapeutic efficacy of paclitaxel in lung cancer therapy

Zou

Chen

et al. 2019

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

Targeted delivery of chemotherapeutics by functionalized nanoparticles exhibits a wonderful prospect for cancer treatment. In this paper, selenium nanoparticles (SeNPs) was linked with hyaluronic acid (HA) to prepare tumor-targeted delivery vehicle HA-SeNPs, and HA-SeNPs was loaded with paclitaxel (PTX) to fabricate functionalized selenium nanoparticles HA-Se@PTX. HA-Se@PTX showed greater uptake in A549 cells in comparison with that in HUVEC, verifying HA-mediated specific uptake of HA-Se@PTX. HA-Se@PTX was capable of entering A549 cells via clathrin-associated endocytosis and showed faster drug release in cancer cell microenvironment in comparison with normal physiological environment. HA-Se@PTX could obviously inhibit the proliferation, migration and invasion of A549 cells and trigger A549 cells apoptosis. Moreover, active targeting functionalized selenium nanoparticles HA-Se@PTX showed greater in vivo antitumor activity compared with free PTX or passive targeting delivery system Se@PTX. In addition, HA-Se@PTX exhibited negligible toxicity on the major organs of mice. In a word, HA-Se@PTX may develop into a valuable nanoscale antitumor drug agent for lung cancer treatment.

show abstract

Boronic acid-tethered amphiphilic hyaluronic acid derivative-based nanoassemblies for tumor targeting and penetration

Cited by 57 publications

References 39 publications

New developments and clinical transition of hyaluronic acid-based nanotherapeutics for treatment of cancer: reversing multidrug resistance, tumour-specific targetability and improved anticancer efficacy

New developments and clinical transition of hyaluronic acid-based nanotherapeutics for treatment of cancer: reversing multidrug resistance, tumour-specific targetability and improved anticancer efficacy

Nanotechnology and sialic acid biology

Hyaluronic acid-modified selenium nanoparticles for enhancing the therapeutic efficacy of paclitaxel in lung cancer therapy

Contact Info

Product

Resources

About